Share this article and save a life!
AI just proved it can catch breast cancer we’re missing.
A groundbreaking Swedish trial of 100,000 women just delivered the evidence we’ve been waiting for.
AI-supported mammography isn’t just hype anymore. The numbers from The Lancet study are striking:
📊 The AI advantage:
• 81% of cancers caught during screening (vs 74% standard)
• 12% fewer interval cancers between screenings
• 44% reduction in radiologist workload
But here’s what matters most:
The AI group found 16% fewer invasive cancers, 21% fewer large tumors, and 27% fewer aggressive cancers.
Think about that. We’re not just finding more cancers, we’re catching them when they’re smaller, less aggressive, and more treatable.
💡 The workforce impact is equally compelling.
With radiologist burnout at crisis levels and screening demand growing, AI acts as a co-pilot, not a replacement. One radiologist plus AI can now do the work that previously required two specialists.
This means shorter wait times for patients and more time for radiologists to focus on complex cases.
The U.S. is taking notice. The PRISM trial just launched with $16 million in funding, testing AI across California, Florida, Massachusetts, Washington, and Wisconsin.
Here’s my take:
We’re witnessing a fundamental shift in cancer screening. AI isn’t replacing clinical judgment, it’s amplifying it. When a technology can simultaneously improve outcomes AND reduce workforce strain, that’s not innovation, that’s transformation.
The question isn’t whether AI belongs in mammography anymore.
It’s how quickly we can scale this to save more lives.
♻️ Repost if earlier cancer detection should be our top priority
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
